Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes

Kieren J. Mather, Amale Lteif, Helmut Steinberg, Alain D. Baron

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Endothelial dysfunction reflects an imbalance of vasodilators and vasoconstrictors. Endogenous endothelin activity seems to be increased in human obesity and type 2 diabetes, and cellular studies suggest that this factor may itself reduce bioavailable nitric oxide (NO). We studied 20 lean, 20 obese, and 14 type 2 diabetic individuals under three protocols, measuring leg vascular responses to intra-arterial infusions of NaG-monomethyl-L-arginine (L-NMMA; an inhibitor of NO synthase) alone or in combination with BQ123 (an antagonist of type A endothelin receptors) or phentolamine (used as a control vasodilator). NO synthase inhibition alone (study 1) produced an ∼40% increase in leg vascular resistance (LVR) in all three participant groups, which was not statistically different across groups (increase in LVR: lean, 135 ± 28; obese, 140 ± 32; type 2 diabetic, 184 ± 51 units; NS). By design, BQ123 at the infused rate of 3 μmol/min produced equivalent ∼35% reductions in LVR across groups. The subsequent addition of L-NMMA produced a greater increase in LVR among obese participants than lean or type 2 diabetic participants (study 2: lean, 182 ± 48; obese, 311 ± 66; type 2 diabetic, 186 ± 40; P = 0.07). Compared with study 1, the effect of L-NMMA was magnified by BQ123 in obese participants but not in lean or type 2 diabetic participants (P = 0.005, study 1 vs. 2; P = 0.03 for group effect). Phentolamine (75 mg/min) produced vasodilation in obese participants comparable to that seen with BQ123 but failed to augment the L-NMMA response. Endothelin antagonism unmasks or augments NO synthesis capacity in obese but not type 2 diabetic participants. This suggests that impaired NO bioavailability as a result of endogenous endothelin may contribute to endothelial dysfunction in obesity, in addition to direct vasoconstrictor effects of endothelin. In contrast, endothelin antagonism alone is insufficient to restore impaired NO bioavailability in diabetes.

Original languageEnglish (US)
Pages (from-to)2060-2066
Number of pages7
JournalDiabetes
Volume53
Issue number8
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Fingerprint

Endothelins
omega-N-Methylarginine
Blood Vessels
Leg
Nitric Oxide
Obesity
Vascular Resistance
Phentolamine
Vasoconstrictor Agents
Vasodilator Agents
Nitric Oxide Synthase
Biological Availability
Intra Arterial Infusions
Vasodilation
Type 2 Diabetes Mellitus
Arginine
cyclo(Trp-Asp-Pro-Val-Leu)

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. / Mather, Kieren J.; Lteif, Amale; Steinberg, Helmut; Baron, Alain D.

In: Diabetes, Vol. 53, No. 8, 01.08.2004, p. 2060-2066.

Research output: Contribution to journalArticle

Mather, Kieren J. ; Lteif, Amale ; Steinberg, Helmut ; Baron, Alain D. / Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. In: Diabetes. 2004 ; Vol. 53, No. 8. pp. 2060-2066.
@article{d4c7fdb7f18d4d6680e7b1a47d54d458,
title = "Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes",
abstract = "Endothelial dysfunction reflects an imbalance of vasodilators and vasoconstrictors. Endogenous endothelin activity seems to be increased in human obesity and type 2 diabetes, and cellular studies suggest that this factor may itself reduce bioavailable nitric oxide (NO). We studied 20 lean, 20 obese, and 14 type 2 diabetic individuals under three protocols, measuring leg vascular responses to intra-arterial infusions of NaG-monomethyl-L-arginine (L-NMMA; an inhibitor of NO synthase) alone or in combination with BQ123 (an antagonist of type A endothelin receptors) or phentolamine (used as a control vasodilator). NO synthase inhibition alone (study 1) produced an ∼40{\%} increase in leg vascular resistance (LVR) in all three participant groups, which was not statistically different across groups (increase in LVR: lean, 135 ± 28; obese, 140 ± 32; type 2 diabetic, 184 ± 51 units; NS). By design, BQ123 at the infused rate of 3 μmol/min produced equivalent ∼35{\%} reductions in LVR across groups. The subsequent addition of L-NMMA produced a greater increase in LVR among obese participants than lean or type 2 diabetic participants (study 2: lean, 182 ± 48; obese, 311 ± 66; type 2 diabetic, 186 ± 40; P = 0.07). Compared with study 1, the effect of L-NMMA was magnified by BQ123 in obese participants but not in lean or type 2 diabetic participants (P = 0.005, study 1 vs. 2; P = 0.03 for group effect). Phentolamine (75 mg/min) produced vasodilation in obese participants comparable to that seen with BQ123 but failed to augment the L-NMMA response. Endothelin antagonism unmasks or augments NO synthesis capacity in obese but not type 2 diabetic participants. This suggests that impaired NO bioavailability as a result of endogenous endothelin may contribute to endothelial dysfunction in obesity, in addition to direct vasoconstrictor effects of endothelin. In contrast, endothelin antagonism alone is insufficient to restore impaired NO bioavailability in diabetes.",
author = "Mather, {Kieren J.} and Amale Lteif and Helmut Steinberg and Baron, {Alain D.}",
year = "2004",
month = "8",
day = "1",
doi = "10.2337/diabetes.53.8.2060",
language = "English (US)",
volume = "53",
pages = "2060--2066",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "8",

}

TY - JOUR

T1 - Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes

AU - Mather, Kieren J.

AU - Lteif, Amale

AU - Steinberg, Helmut

AU - Baron, Alain D.

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Endothelial dysfunction reflects an imbalance of vasodilators and vasoconstrictors. Endogenous endothelin activity seems to be increased in human obesity and type 2 diabetes, and cellular studies suggest that this factor may itself reduce bioavailable nitric oxide (NO). We studied 20 lean, 20 obese, and 14 type 2 diabetic individuals under three protocols, measuring leg vascular responses to intra-arterial infusions of NaG-monomethyl-L-arginine (L-NMMA; an inhibitor of NO synthase) alone or in combination with BQ123 (an antagonist of type A endothelin receptors) or phentolamine (used as a control vasodilator). NO synthase inhibition alone (study 1) produced an ∼40% increase in leg vascular resistance (LVR) in all three participant groups, which was not statistically different across groups (increase in LVR: lean, 135 ± 28; obese, 140 ± 32; type 2 diabetic, 184 ± 51 units; NS). By design, BQ123 at the infused rate of 3 μmol/min produced equivalent ∼35% reductions in LVR across groups. The subsequent addition of L-NMMA produced a greater increase in LVR among obese participants than lean or type 2 diabetic participants (study 2: lean, 182 ± 48; obese, 311 ± 66; type 2 diabetic, 186 ± 40; P = 0.07). Compared with study 1, the effect of L-NMMA was magnified by BQ123 in obese participants but not in lean or type 2 diabetic participants (P = 0.005, study 1 vs. 2; P = 0.03 for group effect). Phentolamine (75 mg/min) produced vasodilation in obese participants comparable to that seen with BQ123 but failed to augment the L-NMMA response. Endothelin antagonism unmasks or augments NO synthesis capacity in obese but not type 2 diabetic participants. This suggests that impaired NO bioavailability as a result of endogenous endothelin may contribute to endothelial dysfunction in obesity, in addition to direct vasoconstrictor effects of endothelin. In contrast, endothelin antagonism alone is insufficient to restore impaired NO bioavailability in diabetes.

AB - Endothelial dysfunction reflects an imbalance of vasodilators and vasoconstrictors. Endogenous endothelin activity seems to be increased in human obesity and type 2 diabetes, and cellular studies suggest that this factor may itself reduce bioavailable nitric oxide (NO). We studied 20 lean, 20 obese, and 14 type 2 diabetic individuals under three protocols, measuring leg vascular responses to intra-arterial infusions of NaG-monomethyl-L-arginine (L-NMMA; an inhibitor of NO synthase) alone or in combination with BQ123 (an antagonist of type A endothelin receptors) or phentolamine (used as a control vasodilator). NO synthase inhibition alone (study 1) produced an ∼40% increase in leg vascular resistance (LVR) in all three participant groups, which was not statistically different across groups (increase in LVR: lean, 135 ± 28; obese, 140 ± 32; type 2 diabetic, 184 ± 51 units; NS). By design, BQ123 at the infused rate of 3 μmol/min produced equivalent ∼35% reductions in LVR across groups. The subsequent addition of L-NMMA produced a greater increase in LVR among obese participants than lean or type 2 diabetic participants (study 2: lean, 182 ± 48; obese, 311 ± 66; type 2 diabetic, 186 ± 40; P = 0.07). Compared with study 1, the effect of L-NMMA was magnified by BQ123 in obese participants but not in lean or type 2 diabetic participants (P = 0.005, study 1 vs. 2; P = 0.03 for group effect). Phentolamine (75 mg/min) produced vasodilation in obese participants comparable to that seen with BQ123 but failed to augment the L-NMMA response. Endothelin antagonism unmasks or augments NO synthesis capacity in obese but not type 2 diabetic participants. This suggests that impaired NO bioavailability as a result of endogenous endothelin may contribute to endothelial dysfunction in obesity, in addition to direct vasoconstrictor effects of endothelin. In contrast, endothelin antagonism alone is insufficient to restore impaired NO bioavailability in diabetes.

UR - http://www.scopus.com/inward/record.url?scp=3242787236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242787236&partnerID=8YFLogxK

U2 - 10.2337/diabetes.53.8.2060

DO - 10.2337/diabetes.53.8.2060

M3 - Article

C2 - 15277386

AN - SCOPUS:3242787236

VL - 53

SP - 2060

EP - 2066

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 8

ER -